Factors related to orthostatic hypotension in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 501-505

  Perez Lloret, Santiago ^a,b   Rey, María Verónica ^a,b   Fabre, Nelly ^c   Ory, Fabienne ^c   Spampinato, Umberto ^d,e   Senard, Jean Michel ^a,f   Pavy Le Traon, Anne ^c   Montastruc, Jean Louis ^a   Rascol, Olivier ^a,b  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b INSERM   (France)

^c CHU PURPAN   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e INSTITUT FRANÇOIS MAGENDIE   (France)

^f UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Aging; Amantadine; Diuretics; Entacapone; Non motor symptoms; Orthostatic hypotension; Parkinson's disease; Polypharmacy

Indexed keywords

AMANTADINE; DIURETIC AGENT; ENTACAPONE; LEVODOPA;

AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PARKINSON DISEASE; PRIORITY JOURNAL; STANDING; SYSTOLIC BLOOD PRESSURE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGE FACTORS; AGED; BLOOD PRESSURE; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; OUTPATIENTS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84861121957     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.01.012     Document Type: Article

References (30)

1. Goldstein D.S. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006, 16:46-54.
2. Senard J.M., Rai S., Lapeyre-Mestre M., Brefel C., Rascol O., Rascol A., et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatr 1997, 63:584-589.
3. Ziemssen T., Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010, 289:74-80.
4. Allcock L.M., Kenny R.A., Mosimann U.P., Tordoff S., Wesnes K.A., Hildreth A.J., et al. Orthostatic hypotension in Parkinson's disease: association with cognitive decline?. Int J Geriatr Psychiatry 2006, 21:778-783.
5. Fedorowski A., Stavenow L., Hedblad B., Berglund G., Nilsson P.M., Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 2010, 31:85-91.
6. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003, 2:669-676.
7. Pazo J.H., Belforte J.E. Basal ganglia and functions of the autonomic nervous system. Cell Mol Neurobiol 2002, 22:645-654.
8. Bouhaddi M., Vuillier F., Fortrat J.O., Cappelle S., Henriet M.T., Rumbach L., et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. Auton Neurosci 2004, 116:30-38.
9. Poon I.O., Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005, 30:173-178.
10. Freeman R., Wieling W., Axelrod F.B., Benditt D.G., Benarroch E., Biaggioni I., et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011, 161:46-48.
11. Bushardt R.L., Massey E.B., Simpson T.W., Ariail J.C., Simpson K.N. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008, 3:383-389.
12. Haensch C.A., Lerch H., Jorg J., Isenmann S. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:134-137.
13. Magerkurth C., Schnitzer R., Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 2005, 15:76-82.
14. Greenland S., Gago-Dominguez M., Castelao J.E. The value of risk-factor (" black-box") epidemiology. Epidemiology 2004, 15:529-535.
15. Jamnadas-Khoda J., Koshy S., Mathias C.J., Muthane U.B., Ragothaman M., Dodaballapur S.K. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?. Mov Disord 2009, 24:1747-1751.
16. Ejaz A.A., Kazory A., Heinig M.E. 24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens (Greenwich) 2007, 9:952-955.
17. Rutan G.H., Hermanson B., Bild D.E., Kittner S.J., LaBaw F., Tell G.S. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992, 19:508-519.
18. Kamaruzzaman S., Watt H., Carson C., Ebrahim S. The association between orthostatic hypotension and medication use in the British Women's Heart and Health Study. Age Ageing 2010, 39:51-56.
19. Brooks D.J. Safety and tolerability of COMT inhibitors. Neurology 2004, 62:S39-S46.
20. Lyytinen J., Sovijarvi A., Kaakkola S., Gordin A., Teravainen H. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease. Clin Neuropharmacol 2001, 24:50-57.
21. Myllyla V.V., Kultalahti E.R., Haapaniemi H., Leinonen M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001, 8:53-60.
22. Eisenhofer G., Finberg J.P. Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J Pharmacol Exp Ther 1994, 268:1242-1251.
23. Rojo A., Fontan A., Mena M.A., Herranz A., Casado S., de Yebenes J.G. Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. Parkinsonism Relat Disord 2001, 7:93-96.
24. Alliance Pharmaceuticals Summary of product characteristics: Symmetrel(R) capsules (Amantadine hydrochloride 100mg) (updated: 19/8/2010) [accessed 24.06.11]. http://www.medicines.org.uk/emc/medicine/4358.
25. Pimentel L., Hughes B. Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. Pediatr Emerg Care 1991, 7:89-92.
26. Hiraoka M., Hirano Y., Kawano S., Fan Z., Sawanobori T. Amantadine-induced after potentials and automaticity in guinea pig ventricular myocytes. Circ Res 1989, 65:880-893.
27. Freeman S.E., Dawson R.M., Culvenor A.J., Keeghan A.M. Interactions of amantadine with the cardiac muscarinic receptor. J Mol Cell Cardiol 1985, 17:9-21.
28. Machado B.H. Neurotransmission of the cardiovascular reflexes in the nucleus tractus solitarii of awake rats. Ann N Y Acad Sci 2001, 940:179-196.
29. Gracious B.L., Krysiak T.E., Youngstrom E.A. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002, 12:249-257.
30. Gallini A., Sommet A., Montastruc J.L. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf 2008, 17:877-881.